Audiological follow-up in transplant patients treated with calcineurin immunosuppressants "Calcineurin inhibitors and Ototoxicity"

Simple item page
dc.contributor.authorHeider, Claudia
dc.contributor.authorWaissbluth, Sofia
dc.contributor.authorOyarzun, Javier A.
dc.contributor.authorCalderara, Gabriela
dc.contributor.authorLeung, Jai-Sen
dc.contributor.authorNovoa, Ivan
dc.date.accessioned2025-01-20T17:14:23Z
dc.date.available2025-01-20T17:14:23Z
dc.date.issued2023
dc.description.abstractBackground: Ototoxicity is a side effect of drugs and medications that usually leads to bilateral and symmetric sensorineural hearing loss that commonly affects the high-frequency range initially, with or preceded by tinnitus. Possible ototoxic side effects of calcineurin inhibitor immunosuppressants have been suggested, but this remains unclear. Therefore, this study aims to evaluate audiological changes in patients undergoing transplantation receiving immunosuppressive treatment with calcineurin inhibitors. Methods: Prospective cohort study. Adult patients undergoing liver or kidney transplantation treated with calcineurin inhibitors were included. Pure-tone audiometry, distortion product otoacoustic emissions, and the Tinnitus Handicap Inventory questionnaire were completed at baseline, one, three, and six months after transplantation. Hearing thresholds were compared and correlated with plasma concentrations of calcineurin inhibitors. Results: Seventeen patients were included, 59% males, with a median age of 54.7 years (29-68 years). Twelve patients underwent liver transplantation, four underwent kidney transplantation, and one patient underwent both. The median follow-up was 5.8 months (4-8 months). Significant pure-tone average shifts were observed in two patients. Both cases presented fluctuations in their hearing levels, which were not bilateral or symmetrical and affected the higher frequencies. All patients received tacrolimus within the therapeutic range during the follow-up period. Three different patients exceeded the expected range once; however, they were rapidly corrected and did not correlate with any changes in hearing. Conclusions: It appears that tacrolimus does not cause hearing loss when levels are within the therapeutic range for a follow-up period of six months post-transplantation.
dc.fuente.origenWOS
dc.identifier.eissn0717-6163
dc.identifier.issn0034-9887
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/91290
dc.identifier.wosidWOS:001197468700004
dc.issue.numero6
dc.language.isoen
dc.pagina.final710
dc.pagina.inicio702
dc.revistaRevista medica de chile
dc.rightsacceso restringido
dc.subjectOtotoxicity
dc.subjectHearing Loss
dc.subjectTacrolimus
dc.subjectCalcineurin Inhibitors
dc.subjectTransplantation
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAudiological follow-up in transplant patients treated with calcineurin immunosuppressants "Calcineurin inhibitors and Ototoxicity"
dc.typeartículo
dc.volumen151
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas